The continued prosperity of a biopharma company is dependent on its ability to keep churning out breakthrough new drugs and turning them into commercial successes backed by a growing body […]
Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit. This is according to a new breakdown from Medidata (PDF), now owned […]
Two biopharmas, Alexion Pharmaceuticals and Karyopharm, are trialing possible treatments while Eli Lilly and Bristol Myers Squibb are offering to help the unemployed stay on their meds. Meanwhile, President Donald […]
Novartis and Aurobindo Pharma USA have signed a mutual agreement to terminate their deal covering the Sandoz US generic oral solids and dermatology businesses. In September 2018, Novartis entered an […]
The cost of taking a drug to market – estimated to be approximately $2.6 billion – combined with increasingly tight healthcare budgets, has put intense pressure on R&D teams. Genomics, […]
